A pilot randomised clinical trial of 670 nm red light for reducing retinopathy of prematurity

Kent, Alison; Abdellatif, Mohamed; Cochrane, Timothy; Broom, Margaret; Dahlstrom, Jane E.; Essex, Rohan W.; Shadbolt, Bruce; Natoli, Riccardo

doi:10.1038/s41390-019-0520-7

Cited by 7 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, the effect of red-light exposure in the prevention of ROP was investigated. Although 670 nm red-light exposure reduced ROP in vivo [ 101 ], the severity and survivability of ROP were similar between the red-light treatment group and the control group in a randomized clinical trial [ 102 ].…”

Section: Rop Therapies Under Investigationmentioning

confidence: 99%

New Aspects on the Treatment of Retinopathy of Prematurity: Currently Available Therapies and Emerging Novel Therapeutics

Ryu

2022

IJMS

View full text Add to dashboard Cite

Retinopathy of prematurity (ROP) is a rare proliferative ocular disorder in preterm infants. Because of the advancements in neonatal care, the incidence of ROP has increased gradually. Now, ROP is one of the leading causes of blindness in children. Preterm infants with immature retinal development are exposed to supplemental oxygen inside an incubator until their cardiopulmonary system is adequately developed. Once they are returned to room air, the relatively low oxygen level stimulates various angiogenesis factors initiating retinal neovascularization. If patients with ROP are not offered adequate and timely treatment, they can experience vision loss that may ultimately lead to permanent blindness. Although laser therapy and anti-vascular endothelial growth factor agents are widely used to treat ROP, they have limitations. Thus, it is important to identify novel therapeutics with minimal adverse effects for the treatment of ROP. To date, various pharmacologic and non-pharmacologic therapies have been assessed as treatments for ROP. In this review, the major molecular factors involved in the pathogenesis of ROP, currently offered therapies, therapies under investigation, and emerging novel therapeutics of ROP are discussed.

show abstract

Section: Rop Therapies Under Investigationmentioning

confidence: 99%

New Aspects on the Treatment of Retinopathy of Prematurity: Currently Available Therapies and Emerging Novel Therapeutics

Ryu

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…The parameters of irradiation used have varied widely, with the variation in the energy density ranging from 0.1 to 25 J/cm 2 , the variation in the irradiance ranging between 8 and 200 mW/cm 2 , and an irradiation duration anywhere between 80 and 250 s ( Table 2 ). However, several studies have reported that PBM plays a negative role in the treatment of progressed AMD, especially accompanied by DME with good visual eyesight [ 32 , 33 , 34 ] ( Table 3 ). Therefore, the progressive stage of retinal diseases is another factor that should be considered when adopting PBM to achieve the best clinical effects.…”

Section: Parameters Of Light Irradiationmentioning

confidence: 99%

Considerations for the Use of Photobiomodulation in the Treatment of Retinal Diseases

et al. 2022

View full text Add to dashboard Cite

Photobiomodulation (PBM) refers to the beneficial effect produced from low-energy light irradiation on target cells or tissues. Increasing evidence in the literature suggests that PBM plays a positive role in the treatment of retinal diseases. However, there is great variation in the light sources and illumination parameters used in different studies, resulting in significantly different conclusions regarding PBM’s therapeutic effects. In addition, the mechanism by which PBM improves retinal function has not been fully elucidated. In this study, we conducted a narrative review of the published literature on PBM for treating retinal diseases and summarized the key illumination parameters used in PBM. Furthermore, we explored the potential molecular mechanisms of PBM at the retinal cellular level with the goal of providing evidence for the improved utilization of PBM in the treatment of retinal diseases.

show abstract

“…Clinical research has demonstrated that low-level laser therapy (LLLT) has an effect within the fields of dermatology, orthopedics, and neurology [7][8][9][10][11]. In ophthalmology, LLLT was also effective in amblyopia in the early stage [12].…”

Section: Introductionmentioning

confidence: 99%

A Study on the Effectiveness of 650-nm Red-Light Feeding Instruments in the Control of Myopia

et al. 2023

View full text Add to dashboard Cite

Introduction: This study analyzed the effectiveness of 650-nm red-light feeding instruments in the control of myopia. Methods: In this study, 164 school-aged participants diagnosed with myopia in the city of Shenzhen were enrolled in a red-light feeding instrument study. Of these, 41 were enrolled in the mild-to-moderate myopia group that received red-light feeding (RLMM group), 65 were enrolled in the mild-to-moderate myopia group that received single-vision spectacle treatment (SVSMM group), and 58 were included in the severe-myopia group that received red-light feeding (RLS group). Results: After the baseline values of the three groups were matched, the right-eye data were used for statistical analysis. The average return-visit time of each group was 60.42 days, and changes in the observation indexes before treatment and after follow-up treatment were compared. As the primary outcome, the axial length changes in the right eye of the SVSMM group (0.08 ± 0.40 mm), the RLMM group (–0.03 ± 0.11 mm), and the RLS group (−0.07 ± 0.11 mm) were compared and showed a statistical result of P < 0.001. Conclusion: The study results verified that red light had a noticeable effect on the control of myopia and that low-level red-light therapy played a vital role in the treatment of severe myopia.

show abstract

A pilot randomised clinical trial of 670 nm red light for reducing retinopathy of prematurity

Cited by 7 publications

References 35 publications

New Aspects on the Treatment of Retinopathy of Prematurity: Currently Available Therapies and Emerging Novel Therapeutics

New Aspects on the Treatment of Retinopathy of Prematurity: Currently Available Therapies and Emerging Novel Therapeutics

Considerations for the Use of Photobiomodulation in the Treatment of Retinal Diseases

A Study on the Effectiveness of 650-nm Red-Light Feeding Instruments in the Control of Myopia

Contact Info

Product

Resources

About